All AbMole products are for research use only, cannot be used for human consumption.

Roquinimex (LS2616; FCF89) is a quinoline-3-carboxamide with potential antineoplastic activity, which increases NK cell activity and macrophage cytotoxicity. Roquinimex at concentrations effective in vivo reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing MNC from MS blood when analysed in vitro.
| Molecular Weight | 308.33 |
| Formula | C18H16N2O3 |
| CAS Number | 84088-42-6 |
| Solubility (25°C) | DMSO ≥ 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[3] Q Liu, et al. Inflamm Res. Roquinimex inhibits dextran sodium sulfate-induced murine colitis
| Related TNF Receptor Products |
|---|
| Lenalidomide
Lenalidomide is a thalidomide analog known to display TNF-α secretion inhibition and possesses immunomodulatory properties. |
| Atrosab
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. |
| Infliximab
Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that blocks TNF-α interaction with TNF-α receptor 1 (TNFR1) and TNFR2. For the treatment of autoimmune diseases. Infliximab is available in BALB/ C or C57/Bl6 mice. |
| Mesaconitine
Mesaconitine is the main active ingredient of Aconitum and has many pharmaceutical effects. |
| Hypaconitine
Hypaconitine is a highly toxic natural active ingredient isolated from aconitum species, which is widely used to study rheumatism. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
